Comparative Pharmacology
Head-to-head clinical analysis: ANTHIM versus SARCLISA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTHIM versus SARCLISA.
ANTHIM vs SARCLISA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oblimersen is an antisense oligonucleotide that inhibits the production of Bcl-2 protein, promoting apoptosis in cancer cells.
Isatuximab is a monoclonal antibody that binds to CD38 on multiple myeloma cells, inducing apoptosis through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). It also inhibits CD38 enzymatic activity.
800 mg IV over 90 minutes, then 400 mg IV over 90 minutes at 2 and 4 weeks post-first dose.
10 mg/kg intravenously weekly for the first 8 weeks, then every 2 weeks thereafter until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life: approximately 21 days (range 12–31 days); supports monthly dosing for post-exposure prophylaxis
Terminal elimination half-life: 9-14 days (approx. 4 weeks to reach steady state in multiple dosing).
Renal: approximately 50% as unchanged drug; biliary/fecal: minimal (<10%)
Renal: ~25% unchanged; Biliary/fecal: minor, primarily metabolized via liver, with metabolites excreted in bile/feces.
Category C
Category C
Monoclonal Antibody
Monoclonal Antibody, Antineoplastic